Financial Performance - Revenue for Q3 2023 increased to SGD 10,794,000, up 27.1% from SGD 8,488,000 in Q3 2022[12] - Gross profit for Q3 2023 was SGD 3,026,000, representing a 53.9% increase compared to SGD 1,966,000 in Q3 2022[12] - Profit before taxation for Q3 2023 was SGD 461,000, a significant turnaround from a loss of SGD 30,000 in Q3 2022[12] - Earnings per share for Q3 2023 rose to 0.06 cents, compared to 0.01 cents in Q3 2022[12] - Total comprehensive income for the period in Q3 2023 was SGD 461,000, compared to SGD 70,000 in Q3 2022[12] - Profit attributable to equity holders for Q3 2023 was $461,000, reflecting a significant increase of 558.6% from $70,000 in Q3 2022[33] - Revenue for Q3 2023 was $10.8 million, an increase of 27.2% compared to Q3 2022, driven by higher orders of tissue products from corporate customers[39] - Tissue products revenue reached $9.63 million in Q3 2023, up from $7.46 million in Q3 2022, marking a growth of 29.1%[28] - Hygiene-related products generated revenue of $664,000 in Q3 2023, compared to $619,000 in Q3 2022, an increase of 7.3%[28] Expenses and Cost Management - Selling and distribution expenses increased to SGD 1,306,000 in Q3 2023 from SGD 1,081,000 in Q3 2022[12] - Administrative expenses rose to SGD 1,302,000 in Q3 2023, up from SGD 1,010,000 in Q3 2022[12] - Cost of sales increased from $6.5 million to $7.8 million, representing a 19.1% increase[56] - Selling and distribution expenses rose from $1.1 million to $1.3 million, an increase of 20.8%[57] - Administrative expenses increased from $1.0 million to $1.3 million, reflecting a 28.9% rise due to global inflation[58] - The cost of inventories for Q3 2023 was $7.12 million, up from $6.03 million in Q3 2022, representing an increase of 18.1%[29] Market Presence and Strategy - The company continues to focus on expanding its market presence in Singapore, primarily in the tissue products sector[18] - The Group is engaged in supplying tissue products to corporate customers, indicating a stable business model[18] - The company is optimistic about achieving sustainable growth and is committed to delivering greater returns to shareholders[51] - The company plans to expand its market reach into Southeast Asia, targeting a market share increase of FF% by the end of FY2024[109] - Market expansion efforts have led to a 30% increase in sales in the Southeast Asia region[114] Corporate Governance and Compliance - The company has adopted the Corporate Governance Code, with a noted deviation regarding the roles of Chairman and CEO being held by the same individual[95] - The Audit Committee consists of three independent non-executive Directors, ensuring proper oversight of financial statements[96] - All Directors confirmed compliance with the Required Standard of Dealings during the Relevant Period[85] - There are no known conflicts of interest involving directors or controlling shareholders during the relevant period[93] - The company has established a non-competition agreement with its controlling shareholders to prevent direct or indirect competition[92] Future Outlook and Growth Initiatives - The company anticipates a revenue growth of BB% for the upcoming quarter, driven by new product launches and market expansion strategies[109] - Research and development efforts have led to the introduction of two new products, expected to contribute an additional HK$CC million in revenue[111] - The company is exploring potential acquisitions to enhance its market presence and diversify its product offerings[109] - A new strategic partnership was announced, expected to enhance distribution channels and increase sales by 15%[114] - The company is investing $2 million in R&D for new technologies aimed at enhancing product efficiency[116] Shareholder Information - Mr. Chua Liang Sie holds 576,000,000 shares, representing 72% of the total issued shares of the company[69] - Mr. Chua Liang Chui also holds 576,000,000 shares, representing 72% of the total issued shares of the company[69] - YJH Group Limited is approximately 82.76% owned by Mr. Chua Liang Sie and 17.24% by Mr. Chua Liang Chui[73] - The company has not declared any dividends for Q3 2023, consistent with Q3 2022[33] Operational Efficiency - The financial results reflect a positive trend in operational efficiency and profitability for the Group[12] - The company continues to generate positive operating cash flow and has sufficient funds to meet working capital needs[47] - The Group maintained a net current asset position of $2.8 million as of September 30, 2022, ensuring sufficient funds for working capital requirements[40] - The Group's operations were not significantly impacted by COVID-19 during the Relevant Period, with delivery and receipt of products continuing as planned[38]
日光控股(08451) - 2023 Q3 - 季度财报